The chimeric monoclonal antibody Rituximab, directed to the CD20 antigen expressed on normal and malignant cells of the B-lymphocytic lineage, has considerably improved treatment of B-cell-derived ...

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in intravenous doses of 3 or 10 ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of coronavirus ...

Market Size and Growth: Analysis of the current market size and projections for the cancer monoclonal antibody market from 2023 to 2032. This includes data on market value and volume, as well as the ...

Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Engineering an antibody against flu with sticky staying power Aerosol treatment adheres to lung lining, blocks infection in mice Date: May 8, 2025 Source: Ohio State University Summary: Scientists ...